Electrolyte-free Parenteral Nutrition Emulsion clinical trials
How each study uses Electrolyte-free Parenteral Nutrition Emulsion is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2019 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 3
Copenhagen University Hospital at Herlev (1) · International Islamic University Malaysia (1) · National Center for Tumor Diseases, Heidelberg (1)
Studies
Open first, then newest update. How each study uses Electrolyte-free Parenteral Nutrition Emulsion is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Early vs Postponed Parenteral Nutrition After Emergency Abdominal SurgeryActive, not recruitingPhase 4Copenhagen University Hospital at HerlevNCT06089551Written as SmofKabiven
- The Impact of IC-Guided Feeding Protocol on Clinical Outcomes in Critically Ill Patients (The IC-Study)CompletedNot applicableInternational Islamic University MalaysiaNCT04479254Written as Enteral Nutrients ( Nutren Optimum, Nutren Diabetes, Novasource Renal ), Parenteral Nutrient ( Smofkabiven)
- Comparing Parenteral Nutrition vs Best Supportive Nutritional Care in Patients With Pancreatic CancerTerminatedPhase 3National Center for Tumor Diseases, HeidelbergNCT01362582Written as SMOF Kabiven